Denny Lanfear is a biosimilar pioneer and biopharmaceutical leader with a proven track record of successful entrepreneurial vision and achievement. In 2010, after decades working in the biopharmaceutical industry, he founded Coherus BioSciences with the vision of improving the public’s access to high-quality, life-changing medicines. Under Mr. Lanfear’s leadership as President, CEO, and Chairman, Coherus BioSciences was transformed from an unfunded startup into the industry’s leading pure play biosimilar company, with over $1.25 billion in funding being raised since its inception. Coherus has experienced outstanding success with the launch of its first drug, UDENYCA® (pegfilgrastim-cbqv).
A dedicated entrepreneur, Mr. Lanfear founded two other companies before Coherus BioSciences: Saronyx, Inc., a drug development software services company and the biopharmaceutical company InteKrin Therapeutics. He served as CEO of both firms.
Mr. Lanfear held various senior leadership roles at Amgen Inc., serving as Vice President of Process Development before transitioning to the Commercial side of the business as Vice President of Market Development. The Process Development department was initiated and became a key strategic advantage for the company under his leadership. During his 13-year tenure at Amgen he also acquired substantial operations experience, and was tasked with integrating more than 2,500 operations and staff worldwide after the company’s explosive growth. Mr. Lanfear’s product development experience includes various leadership positions with multiple product development programs including growth factors, somatotrophins, and neurotrophins, having directed efforts from preclinical studies to Phase 3 clinical trials.
Mr. Lanfear currently serves on the board of directors of NEUVOGEN, Inc.
Mr. Lanfear holds B.S. degrees in Chemical Engineering and Biochemistry from Michigan State University and an M.B.A. from the Anderson School of Management at the University of California, Los Angeles.
What is Dennis M. Lanfear's net worth?
The estimated net worth of Dennis M. Lanfear is at least $1.77 million as of November 22nd, 2023. Mr. Lanfear owns 731,693 shares of Coherus BioSciences stock worth more than $1,770,697 as of March 28th. This net worth evaluation does not reflect any other investments that Mr. Lanfear may own. Additionally, Mr. Lanfear receives a salary of $1,790,000.00 as CEO at Coherus BioSciences. Learn More about Dennis M. Lanfear's net worth.
How old is Dennis M. Lanfear?
What is Dennis M. Lanfear's salary?
How do I contact Dennis M. Lanfear?
Has Dennis M. Lanfear been buying or selling shares of Coherus BioSciences?
Dennis M. Lanfear has not been actively trading shares of Coherus BioSciences within the last three months. Most recently, Dennis M. Lanfear sold 223,100 shares of the business's stock in a transaction on Wednesday, November 22nd. The shares were sold at an average price of $2.02, for a transaction totalling $450,662.00. Following the completion of the sale, the chief executive officer now directly owns 731,693 shares of the company's stock, valued at $1,478,019.86. Learn More on Dennis M. Lanfear's trading history.
Who are Coherus BioSciences' active insiders?
Are insiders buying or selling shares of Coherus BioSciences?
In the last twelve months, insiders at the biotechnology company sold shares 1 times. They sold a total of 223,100 shares worth more than $450,662.00. The most recent insider tranaction occured on November, 22nd when CEO Dennis M Lanfear sold 223,100 shares worth more than $450,662.00. Insiders at Coherus BioSciences own 11.0% of the company.
Learn More about insider trades at Coherus BioSciences. Information on this page was last updated on 11/22/2023.